Click the button above to generate a structured intelligence briefing based on the latest industry data.
Research Frontiers (12)
Industry Funding (7)
Ginkgo Bioworks
2025-11-20
Follow-on
Ginkgo Bioworks raised $300M follow-on funding to expand its cell programming platform and biosecurity division, targeting pharmaceutical and agricultural applications.
Huamei Haolian (华美浩联)
2025-10-15
D
Huamei Haolian completed D-round financing for its Pichia pastoris-based recombinant collagen production platform, targeting medical aesthetics and regenerative medicine markets.
Amyris (now Aprinnova)
2025-09-28
Strategic
Aprinnova (formerly Amyris) secured strategic investment to scale its yeast-based squalane and specialty ingredients platform for cosmetics and nutrition markets.
Invaio Sciences
2025-08-12
B
Invaio Sciences raised Series B to develop Pichia-produced biopesticides and crop enhancement biologicals using its proprietary delivery platform.
Conagen
2025-07-05
C
Conagen closed Series C for its precision fermentation platform producing high-value ingredients including recombinant human milk oligosaccharides (HMOs) in engineered yeast.
Spiber
2025-06-20
Series F
Spiber raised Series F to scale production of Brewed Protein™ structural proteins using precision fermentation, with new facilities in Thailand targeting 10,000 MT/year capacity.
Tropic Biosciences
2025-05-10
C+
Tropic Biosciences extended its Series C for gene-edited crop development, including yeast-produced RNA-based crop protection agents.
Policy & Regulation (7)
China's 14th Five-Year Plan for Bio-Manufacturing: Key Implementation Guidelines Released
NDRC & MIIT
New guidelines prioritize synthetic biology as a strategic emerging industry, with ¥50B in government-backed funds for bio-manufacturing infrastructure, microbial cell factories, and green biomanufacturing demonstration projects through 2027.
EU Novel Food Regulation Update: Streamlined Approval for Precision Fermentation Products
EFSA
EFSA published updated guidance for precision fermentation-derived food ingredients, introducing a fast-track approval pathway for GRAS-equivalent organisms including Pichia pastoris, reducing approval timeline from 24 to 12 months.
US Executive Order on Biotechnology: $2B National Biomanufacturing Initiative
White House OSTP
Building on the 2022 Executive Order, the new initiative allocates $2B over 5 years for domestic biomanufacturing capacity, including $400M for microbial fermentation infrastructure and workforce training programs.
Japan's Green Growth Strategy: Synthetic Biology Designated as Key Technology Area
METI
Japan's METI designated synthetic biology as one of 14 key technology areas under the Green Growth Strategy, with ¥200B ($1.4B) in R&D funding through 2030, focusing on bio-based materials and pharmaceutical production.
Singapore Bioeconomy Blueprint: Tax Incentives for Precision Fermentation Companies
EDB Singapore
Singapore announced 10-year tax holidays and 50% co-investment grants for precision fermentation companies establishing manufacturing facilities, positioning itself as Asia's biomanufacturing hub.
Brazil ANVISA Approves Fast-Track for Recombinant Protein Therapeutics from Yeast Systems
ANVISA
ANVISA established a priority review pathway for biosimilars produced in yeast expression systems, recognizing Pichia pastoris as a well-characterized host with established safety profiles, reducing review time by 40%.
UK Genetic Technology Act Amendment: Simplified Regulations for Engineered Microorganisms
DEFRA
Post-Brexit regulatory reform simplifies contained-use notifications for engineered yeast and bacteria in industrial fermentation, aligning with industry calls for proportionate risk-based regulation.